Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04859517 · ClinicalTrials.gov registry record · Phase 2
Evaluation of ADG20 for the Prevention of COVID-19
A Phase 2 study, sponsored by Invivyd.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2,582
- Enrollment target
NCT04859517: Clinical Trial Phase 2 study, sponsored by Invivyd.
NCT04859517 is a Phase 2 study that was terminated before completion, run by Invivyd. The registered enrollment target is 2,582 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1841% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04859517, a Phase 2 study, was terminated before completion, sponsored by Invivyd.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2,582 participants
- Enrollment target
Study Summary
This placebo-controlled study is intended to evaluate ADG20's safety and ability to prevent COVID-19 infection.
Primary Outcome
RT-PCR-confirmed symptomatic COVID-19 is determined by a positive central or local (in the absence of central test) RT-PCR test from a nasopharyngeal or saliva sample accompanied by protocol-defined COVID-19 symptoms occurring within 14 days from the sample collection date. Any COVID-19-related hospitalization with a positive local SARS-CoV-2 test (within 14 days) or all-cause death are counted toward the endpoint.
Interventions
- DRUG Placebo
- DRUG ADG20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,582 participants |
| Start Date | 2021-04-27 |
| Est. Completion | 2022-11-04 |
| Phase | Phase 2 |
Why NCT04859517 stopped before completion
NCT04859517 is an interventional study that assigns participants to a tested intervention. Its 2,582 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1841% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04859517 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04859517 about?
NCT04859517 is a clinical study titled "Evaluation of ADG20 for the Prevention of COVID-19". This placebo-controlled study is intended to evaluate ADG20's safety and ability to prevent COVID-19 infection.
What is the current status of trial NCT04859517?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2,582 participants. The study started on 2021-04-27. Estimated completion is 2022-11-04.
What interventions are being tested in trial NCT04859517?
The interventions under investigation include: Placebo (DRUG), ADG20 (DRUG).
Who is sponsoring clinical trial NCT04859517?
This trial is sponsored by Invivyd, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04859517's enrollment target sits among peer trials
2,582 7th of 2000 higher than 1,994 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06370520 · 2,592 participants
Screening Emotions in Adolescents at the Hospital for mTBI
- NCT06018285 · 2,572 participants · NA
Stepped Approach to Reducing Risk of Suicide in Primary Care
- NCT06033950 · 2,600 participants · Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
- NCT06574672 · 2,600 participants · NA
Embedded Palliative Care in the MICU
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI